Illumina introduces TruPath Genome, setting a new standard in genomic insight: San Diego Thursday, February 26, 2026, 16:00 Hrs [IST] Illumina, Inc. announced the launch of TruPat ...

Adeno-associated viruses (AAV) are powerful instruments in gene therapy. AAV particles comprise a protein capsid that along with the desired genome, containing both is considered a full capsid.

TruPath™ Genome offers more complete genome, with the simplest sample to sequencer workflow, and the new AGBT data ...

The presence or absence of remaining foreign DNA from the crossbred progeny of the genome-edited crop and the original crop cultivar can be determined by GenEditScan, based on the k-mer method.

Bionano Symposium 2026 continues with Day 3: OGM Making its Mark in Constitutional Genetic Disorders on February 25, 2026, from 7:00-10:00 AM PT. Attendees may also explore scientific posters ...

Growing Adoption of Gene Therapy Platforms, Expanding Agricultural Biotechnology Applications, and Accelerating Clinical Trial Activity Drive Robust Market Expansion.Austin, United States, Feb. 27, ...

Nabsys 2.0, LLC (Nabsys), a pioneer in electronic genome mapping (EGM) technology, today announced new findings presented at the Advances in Genome Biology and Technology (AGBT) 2026 meeting. The data ...

A new comparison and analysis of the genomes of species in the genus Malus, which includes the domesticated apple and its wild relatives, revealed the evolutionary relationships among the species and ...

A new blended genome genetic test being studied in a major clinical trial may help identify men at highest risk of aggressive prostate cancer and personalise screening strategies.

Genetic modification of viruses has long been used as a strategy to treat and prevent different types of diseases. Specifically, it consists of exploiting certain characteristics of viruses that make ...